ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 150 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $223,668 | -2.8% | 4,808 | +8.4% | 0.00% | 0.0% |
Q3 2022 | $230,000 | +11.7% | 4,434 | +2.1% | 0.00% | 0.0% |
Q2 2022 | $206,000 | -55.0% | 4,342 | -32.5% | 0.00% | 0.0% |
Q1 2022 | $458,000 | -19.6% | 6,433 | -15.7% | 0.00% | 0.0% |
Q4 2021 | $570,000 | +38.3% | 7,633 | +5.3% | 0.00% | 0.0% |
Q3 2021 | $412,000 | +2.7% | 7,249 | -20.5% | 0.00% | 0.0% |
Q2 2021 | $401,000 | -4.1% | 9,114 | +7.7% | 0.00% | 0.0% |
Q1 2021 | $418,000 | +29.4% | 8,466 | +10.5% | 0.00% | 0.0% |
Q4 2020 | $323,000 | +19.6% | 7,662 | +30.0% | 0.00% | 0.0% |
Q3 2020 | $270,000 | -11.2% | 5,894 | -2.7% | 0.00% | -50.0% |
Q2 2020 | $304,000 | +44.8% | 6,055 | +48.1% | 0.00% | 0.0% |
Q1 2020 | $210,000 | -51.6% | 4,088 | -41.9% | 0.00% | 0.0% |
Q4 2019 | $434,000 | -6.1% | 7,031 | -8.5% | 0.00% | -33.3% |
Q3 2019 | $462,000 | -31.4% | 7,686 | -3.6% | 0.00% | -25.0% |
Q2 2019 | $673,000 | -20.6% | 7,974 | -10.2% | 0.00% | -20.0% |
Q1 2019 | $848,000 | +36.1% | 8,879 | +1.0% | 0.01% | +25.0% |
Q4 2018 | $623,000 | -29.6% | 8,791 | -15.1% | 0.00% | -33.3% |
Q3 2018 | $885,000 | -29.1% | 10,351 | -3.9% | 0.01% | -25.0% |
Q2 2018 | $1,248,000 | +36.7% | 10,772 | -4.6% | 0.01% | +33.3% |
Q1 2018 | $913,000 | +19.5% | 11,286 | -13.3% | 0.01% | +20.0% |
Q4 2017 | $764,000 | +35.0% | 13,023 | +7.6% | 0.01% | 0.0% |
Q3 2017 | $566,000 | +38.4% | 12,098 | +6.4% | 0.01% | +25.0% |
Q2 2017 | $409,000 | +8.2% | 11,375 | -7.4% | 0.00% | 0.0% |
Q1 2017 | $378,000 | -26.7% | 12,284 | -20.2% | 0.00% | -33.3% |
Q4 2016 | $516,000 | +40.2% | 15,393 | +11.4% | 0.01% | +20.0% |
Q3 2016 | $368,000 | +2.2% | 13,820 | -15.3% | 0.01% | 0.0% |
Q2 2016 | $360,000 | -24.7% | 16,318 | +0.3% | 0.01% | -28.6% |
Q1 2016 | $478,000 | -18.3% | 16,270 | -8.1% | 0.01% | 0.0% |
Q4 2015 | $585,000 | +0.9% | 17,703 | +10.3% | 0.01% | -12.5% |
Q3 2015 | $580,000 | -24.0% | 16,044 | -5.4% | 0.01% | -27.3% |
Q2 2015 | $763,000 | +46.2% | 16,955 | -0.6% | 0.01% | +83.3% |
Q1 2015 | $522,000 | -29.4% | 17,049 | +17.4% | 0.01% | -33.3% |
Q4 2014 | $739,000 | +240.6% | 14,527 | +188.5% | 0.01% | +200.0% |
Q2 2014 | $217,000 | – | 5,036 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |